ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter 2025 financial re ...

MedRobot 全球医疗机器人与智能外科大奖（MedRobot Awards）申报通知 ——寻找中国智能医疗产业的关键推动者 全球医疗机器人与智能外科大奖（MedRobot Awards 2025）现面向全行业开启奖项申报。欢迎整机厂商、 上游供应链企业/服务机构；企业家、转化专家等申报相关奖项。 MedRobot相信： 以手术机器人为代表的智能外科产品服务，正在成为未来十年医疗科技最具爆发力的领域，而推动技术进 步、临床转化与产业协同的每一环节，都值得被看见与尊重！ 颁奖典礼将在第三届全球手术机器人大会现场举行；中英文奖项名单同步在海内外发出。 评奖初衷 MedRobot Awards 设立的初心 ，是在过去多年手术 机器人奖项基础上， 全面升级评奖视角与产业认知 ： 从"整机"到"系统"： 不再仅仅关注机器人本体，更关注术前-术中-术后的数据闭环、术式优化、软硬融合等系统化能力。 从"设备"到"生态"： 医疗机器人不只是单品创新，更依赖核心零部件、算法支持、制造工艺、医疗场景验证等生态协同。 从"单点突破"到"产业闭环"： 不仅表彰技术先锋，也鼓励在商业模式、供应链协同、医院合作、国际拓展等维度有贡献的 ...

Core Insights - SS Innovations International, Inc. has successfully completed the world's first intercontinental robotic cardiac telesurgery, showcasing the capabilities of its SSi Mantra 3 surgical robotic system [1][4][6] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [1][8] - The company has received regulatory approval from India's Central Drugs Standard Control Organization for both teleproctoring and telesurgery, distinguishing it from other surgical robotic companies [7] Surgical Achievements - The recent cardiac procedure involved a robotic atrial septal defect closure performed remotely from Strasbourg, France to Indore, India, covering a distance of over 4,000 miles [2][3] - To date, SS Innovations has completed 35 telesurgeries, including 10 cardiac procedures, demonstrating the effectiveness of the SSi Mantra system in complex surgeries [6] Technological Features - The SSi Mantra surgical robotic system includes advanced features such as modular robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models, enhancing surgical precision and safety [12]

Performed by Dr. Sudhir Srivastava utilizing the Company’s SSi Mantra 3 surgical robotic system Remotely conducted from IRCAD in Strasbourg, France, at an unprecedented distance of more than 4,000 miles to the operating room at SAIMS in Indore, India FORT LAUDERDALE, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible ...

Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, a ...

Core Insights - SS Innovations International, Inc. has installed over 100 SSi Mantra surgical robotic systems across India and six other countries, with more than 5,000 surgical procedures performed to date, including 240 cardiac surgeries and 32 telesurgeries [1][2] - The company aims to democratize access to robotic surgery and plans to submit a De Novo application to the U.S. FDA for marketing approval of the SSi Mantra by the end of July 2025, while also pursuing CE marking certification in the European Union by late 2025 [2] Company Overview - SS Innovations develops innovative surgical robotic technologies with a focus on affordability and accessibility for a larger segment of the global population, featuring the SSi Mantra surgical robotic system and the SSi Mudra surgical instruments [3] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Product Details - The SSi Mantra surgical robotic system is a modular, multi-arm system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models [4] - It has been clinically validated in over 100 different types of surgical procedures, supporting various specialties, including cardiac surgery [4]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant milestone in the field of robotic surgery [2][3][5] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [2][7] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [7] Surgical Procedure Details - The telesurgery involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, which are advanced bariatric procedures aimed at long-term weight loss and improved metabolic health [4][8] - The surgeries were performed remotely over a distance of 560 miles, showcasing the capabilities of the SSi Mantra 3 system with zero perceptible lag and flawless precision [3][8] Technological Advancements - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities, supporting various surgical specialties [11] - The system has been clinically validated in over 100 different types of surgical procedures in India, demonstrating its versatility and effectiveness [11] Vision and Impact - The company emphasizes its mission to democratize robotic surgery, bridging healthcare gaps and making advanced surgical care accessible to remote regions [5][6] - SS Innovations aims to redefine surgical care access, equity, and excellence through its innovative technologies and humanitarian vision [6]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant advancement in robotic surgery technology [1][4] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [5] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [5] Technological Achievement - The robotic telesurgery bridged a distance of 560 miles between Gurugram and Indore, India, performed with zero perceptible lag and flawless precision [2][7] - The procedures involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, showcasing the capabilities of the SSi Mantra 3 system [3][7] Leadership Commentary - Dr. Sudhir Srivastava, CEO, emphasized that this achievement bridges healthcare gaps and makes advanced surgical expertise accessible to remote regions [4] - Dr. Mohit Bhandari, who led the surgery, highlighted the potential of robotic telesurgery to redefine surgical care and improve access to healthcare [4] Future Vision - SS Innovations aims to continue refining its technology to enhance surgical efficiency and improve patient outcomes, particularly in underserved areas [4]

Core Viewpoint - Medtronic plc has appointed Chad Spooner as the chief financial officer (CFO) of MiniMed, ahead of its planned separation into a standalone public company, effective July 14, 2025 [1][5]. Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [8]. - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions through various technologies and therapies [8]. Leadership Appointment - Chad Spooner brings over 25 years of financial leadership experience in healthcare, consumer, and industrial sectors, previously serving as CFO at BIC and holding senior finance roles at General Electric and other companies [2][4]. - His appointment is seen as crucial for driving transformation and growth as MiniMed prepares for independence [3][4]. MiniMed Separation - Medtronic announced that MiniMed will be the name of the new standalone company, honoring its 40-year legacy in diabetes care [3]. - The separation is expected to be completed within 18 months of the initial announcement, subject to customary conditions and legal requirements [5]. Mission and Vision - MiniMed's mission is to make diabetes management more predictable, enhancing the lives of individuals with diabetes through advanced technology and support [7].

Core Insights - Medtronic plc has appointed Dr. Joon Lee, CEO of Emory Healthcare, as an independent director on its Board, effective June 18, 2025 [1] - Dr. Lee will contribute to the Science and Technology Committee and Compensation and Talent Committee [1] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies [6] Dr. Joon Lee's Background - Dr. Lee has over 25 years of experience at the University of Pittsburgh Medical Center (UPMC), where he held significant roles including Executive Vice President and President of Physician Services [3] - He has a strong background in cardiology, having served as Chief of the Division of Cardiology and founding executive director of the UPMC Heart and Vascular Institute [4] - Dr. Lee's educational credentials include a BA from Dartmouth College and an MD from Duke University, along with extensive training in cardiology at Massachusetts General Hospital [5] Financial and Operational Insights - Emory Healthcare, under Dr. Lee's leadership, generates $7.7 billion in annual revenue and operates 12 hospitals with over 29,000 employees [2] - Dr. Lee also served as Chief Medical Officer of UPMC Insurance Services, which is a $13 billion health insurance division [4] Strategic Vision - Dr. Lee is recognized for his commitment to leveraging data and technology to enhance patient and provider experiences, aligning with Medtronic's mission [2]